reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
ONWARD® Medical Announces Participation in Stifel European Healthcare ...
ONWARD® Medical Announces Participation in Stifel European Healthcare Summit CEO Dave Marver will meet with investors to discuss the Company’s achievements and upcoming milestones EINDHOVEN, the Netherlands, June 26, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its participation in the Stifel European Healthcare Summit in Lyon, France from June 25-27th. CEO Dave Marver will mee...
UCB SA: 1 director
A director at UCB SA sold/sold after exercising options 12,460 shares at 136.500EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal M...
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE (Euro...
MaaT Pharma annonce l’initiation de la couverture de son titre par Sti...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce l’initiation de la couverture de son titre par la banque d’investissement américaine, Stifel. Avec une étude publiée ce jour, Stifel a initié la couverture aujourd’hui de MaaT Pharma avec une recommandation à l’achat et un objectif de cours à 16 euros. Stifel est une banque d'investissement de premier plan basé...
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel wi...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Stifel, a US-based investment bank. With a research report published today, Stifel initiated coverage of MaaT Pharma with a Buy recommendation and a Target Price of EUR 16. Stifel is a US-based full-service investment bank offering securities brokerage, trading, research, underwriting, ...
MaaT Pharma nomme Docteur Gianfranco Pittari, M.D., PhD, au poste de d...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce aujourd'hui la nomination de Gianfranco Pittari, docteur en médecine et PhD., au poste de Directeur médical (Chief Medical Officer). Dr Pittari apporte plus de 15 ans d'expérience internationale dans la recherche clinique et le développement de candidats-médicaments en hématologie, oncologie et immunologie. Il rejo...
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical O...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer. Dr. Pittari brings over 15 years of international experience in clinical research and drug development in hematology, oncology, and immunology. He will join the executive management team and oversee the clinical programs of the Company’s innovative ...
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Jeremy Garnier
- Marc Lavaud
- Nicolas Thorez
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/24/2024
Dutch real estate companies showed signs of cautious optimism at the recent Provada conference, with logistics and retail favoured. Healthcare shows some positive signs, with limited devaluations. The Dutch government's potential reduction of the Real Estate Transfer Tax and new REIT regime could benefit listed real estate companies active in the country. - ...
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
SOI SOITEC SA
ELI ELIA GROUP SA/NV
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
IBE IBERDROLA SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RACE FERRARI NV
BHP BHP GROUP LTD
ARGX ARGEN-X SE
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
- Bruno Cavalier
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Jeremy Garnier
- Marc Lavaud
- Nicolas Thorez
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 24/06/2024
Dutch real estate companies showed signs of cautious optimism at the recent Provada conference, with logistics and retail favoured. Healthcare shows some positive signs, with limited devaluations. The Dutch government's potential reduction of the Real Estate Transfer Tax and new REIT regime could benefit listed real estate companies active in the country. - ...
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
SOI SOITEC SA
ELI ELIA GROUP SA/NV
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
IBE IBERDROLA SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RACE FERRARI NV
BHP BHP GROUP LTD
ARGX ARGEN-X SE
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
- Damien Choplain
- Martial Descoutures
Argenx : Green light from the FDA for Vygart Hytrulo in CIDP
>Vyvgart Hytrulo approved in CIDP - Last Friday evening, Vyvgart Hytrulo (subcutaneous version of Vyvgart) obtained FDA approval for use in chronic inflammatory demyelinating polyneuropathy (CIDP), the second indication approved in the US after Myasthenia Gravis (MG). The product has been granted a broad label and can therefore be prescribed for all patients with CIDP and throughout the treatment algorithm, which we consider to be a best-case scenario. This approval i...
- Damien Choplain
- Martial Descoutures
Argenx : Feu vert de la FDA pour Vyvgart Hytrulo dans la CIDP
>Vyvgart Hytrulo approuvé dans la CIDP - Vendredi soir dernier Vyvgart Hytrulo (version sous-cutanée de Vyvgart) a obtenu l’approbation de la FDA pour une utilisation dans la polyneuropathie inflammatoire démyélinisante chronique (CIDP), deuxième indication approuvée aux US après la Myasthénie Grave (MG). Le produit a obtenu un label large et pourra donc être prescrit chez tous les patients atteints de CIDP et tout au long de l’algorithme de traitement, ce que nous co...
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx CIDP joins the party
argenx meets and exceeds our expectations with a broad label approval for CIDP, the 2nd approved indication in the US, which unlocks Vyvgart regardless of prior therapies. Based on updated patient population estimates and a premium $ 450k net pricing, we upgrade our peak sales estimate from $ 3.05bn to $ 3.76bn and increase our TP to € 460 (previously € 420 while we reiterate our Buy rating.
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammat...
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART® and VYVGART Hytrulo franchise Management to host conference call on June 21, 2024 at 11:00pm CET (5:00pm ET) June 21, 2024, 4:40pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global imm...
Description of the Share Repurchase Program Authorised by the Ordinary...
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary General Meeting of 20 June 2024, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the...
Results of the votes of the Combined Shareholders’ General Meeting of ...
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réu...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce les ...
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx Preview on FDA's CIDP decision
CIDP could become the second marketed neuromuscular indication for efgartigimod in the US following gMG, pending expected FDA approval on June 21, 2024. In July 2023, argenx announced that it obtained positive topline data in its ADHERE study, featuring a 67% response rate in Stage A, and a primary endpoint hit in Stage B with a 61% reduction in risk of relapse versus placebo. We believe that efgartigimod could confer a treatment benefit over current treatment standards with sustained efficacy o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.